Tatalaksana terkini pada miastenia gravis

Abstract

Myasthenia gravis (MG) is a disorder of the neuromuscular junction that causes fluctuating muscle weakness. The etiology of this disease is due to the presence of antibodies that attack acetylcholine receptors on the postsynaptic membrane (autoimmune). Myasthenia gravis is a chronic disease and most MG patients fall into Generalized Myasthenia Gravis (gMG) within 2 years of onset. Myasthenic crisis is a serious condition and requires high-cost management. Therefore, disease management continues to be updated to reduce mortality and mortality, as well as improve quality of life. This article discusses the latest myasthenia gravis; guidelines 2020 ; immunosuppressants; plasmaparesis; ivig

Keywords

• myasthenia gravis
• guidelines 2020
• immunosuppressants
• plasmaparesis
• ivig